HIGHLIGHTS
- who: Uveal melanoma et al. from the Department of Clinical Neuroscience, Division of Eye and Vision have published the research work: A protein signature at the time of patient, in the Journal: (JOURNAL)
- what: The authors have developed a prognostic test for UM based on a single peripheral blood sample that is obtained at the time of diagnosis. The authors demonstrate that a low, intermediate, and high metastatic risk category can be defined based on serum leptin and osteopontin levels, and that patients have shorter metastasis-free- and overall survival as well as a greater . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.